2026 Northwest Allergy Forum (NWAF)

Seattle, WA US
October 9, 2026 to October 11, 2026

The NWAF is an annual educational conference hosted on alternate years by the Washington and Oregon Societies of Allergy, Asthma and Immunology.  This year, the NWAF will be hosting by the WSSAAI.  The conference is attended by allergists, Fellows in Training, physicians in related specialties as well as Residents, Medical Students and Nurses. The 2-day program with both local and national speakers will cover disease states such as urticaria, food allergy, asthma, angioedema, biologic therapies, and online advocacy.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Washington State Society of Allergy, Asthma & Immunology (WSSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 9 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 9 contact hours.

No commercial support was received for this activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this activity learners should be able to…

1. Appraise current and emerging therapies, including oral and intralymphatic immunotherapy, in terms of safety, adherence, and long-term outcomes compared to strict avoidance.
2. Apply clinical practice guidelines to the management of patients with CSU.
3. Propose strategies for timely specialist referral, multidisciplinary collaboration, and patient education to optimize biologic use, adherence, and long-term asthma outcomes.
4. Consolidate evidence on the identification and management of uncontrolled and severe asthma, incorporating phenotype, endotype, and biomarker assessment to guide individualized treatment.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary

Available credit: 
  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Course opens: 
10/09/2026
Course expires: 
12/31/2026
Event starts: 
10/09/2026 - 12:00pm CDT
Event ends: 
10/11/2026 - 12:00pm CDT
Rating: 
0

WSSAAI: Northwest Allergy Forum
October 9-11, 2026
Hyatt at Olive 8  Seattle, WA

All Education Sessions to be held in Ballroom A, B
Exhibits and Coffee Breaks to be held in Ballroom C, D, E

Friday, October 9

5:00-6:00pm     Registration, Exhibits & Welcome Reception 

6:00-7:00pm    Dinner Program 
Operational Efficiency / Q&A - Kristina James, MD
brought to you by the Washington State Society of Allergy, Asthma and Immunology and the American College of Allergy, Asthma & Immunology

Saturday, October 10 

6:30-7:50am    Exhibits | Registration | Coffee Break 

NWAF General Session 

7:50-8:00am    Welcome & Introduction – Albert Tsien, MD, WSSAAI
Session Moderator – Albert Tsien, MD, WSSAAI

8:00-9:00am     Global Innovations and Breakthroughs in Urticaria Management / Q&A - Jonathan A. Bernstein, MD

9:00-10:00am     Angioedema Without Itch / Q&A - Jonathan A. Bernstein, MD

10:00-10:30am    Coffee Break | Exhibits

10:30-11:30am     Asthma Inception: Clinical and Molecular Phenotypes in Early Life / Q&A - Matthew C. Altman, MD

11:30am-12:30pm    Mechanisms and Predictors of Response (or Failure) to Biologic Therapies in Asthma and Allergy / Q&A - Matthew C. Altman, MD

12:30pm    Adjourn

Sunday, October 11  

7:00-8:00am    Exhibits | Coffee Break 

NWAF General Session 

7:50-8:00am    Welcome & Introduction
Session Moderator – Rahool Davé, MD, WSSAAI

8:00-9:00am        The Latest in Treatment Options for Food Allergy / Q&A - Julie Wang, MD

9:00-10:00am     From Bedside to Newsfeed: The Allergist’s Role in Combating Misinformation and Advancing Advocacy Online / Q&A - Payel Gupta, MD

10:00-10:30am     Coffee Break | Exhibits                     

10:30-11:30am     FPIES: Food Protein Induced Enterocolitis Syndrome / Q&A - Julie Wang, MD

11:30am-12:30pm     Beyond the Waiting Room: How Allergists Can Use Social Media to Educate, Engage, and Build Trust / Q&A - Payel Gupta, MD

12:30pm        Adjourn

Hyatt at Olive 8
1635 8th Avenue
Seattle, WA 98101
United States

All relevant financial relationships with ineligible companies have been mitigated.

Jonathan A Bernstein, MD – Speaker
Consultant: Astria, Allakos, Amgen, Apogee, AstraZeneca, Aquestive, Biocryst, Blueprint Medicines, Celldex Therapeutics, CSL Behring, Eli Lilly, Enanta, Fresenius Kabi, Genentech, GSK, Hikma Pharmaceuticals, Ionis, Incyte, Japanese Tobacco Company, Jasper, Johnson and Johnson, KalVista Pharmaceuticals, Kenvue, Kymeria, Kyowa Kirin, Labcorp, Lycia, Nasus, Neffy, Novartis, Nurix, Opella, Pfizer, Pharming, RAPT, Regeneron Pharmaceuticals Inc., Sanofi, Shire/Takeda, Teledoc, Yuhan
Researcher: Astria, ADARx, Allakos, Amgen, ARS,  AstraZeneca, Biocryst, Blueprint Medicines, Celldex Therapeutics, Cogent, CSL Behring, Eli Lilly, Escient, Evommune, Fresenius Kabi, Genentech, GSK, Ionis, Incyte, Intellia, Jasper, Johnson and Johnson, KalVista Pharmaceuticals, Labcorp, Merck, Nasus, Novartis, Pfizer, Pharming, Regeneron Pharmaceuticals Inc., Sanofi, Shire/Takeda, TEVA, Yuhan
Speaker: CSL Behring, Kalvista, Novartis, Pharming

Rahool Davé, MD – Planner
Advisor: Cogent, Novartis, Sanofi
Consultant: Novartis, Sanofi
Speaker: AstraZeneca, GSK, Sanofi

T. Ted Song, MD – Planner
Speaker: ARS Pharma, AstraZeneca

Julie Wang, MD – Speaker
Independent contractor: DBV Technologies, GSK, Siolta

The following have no relevant financial relationships with ineligible companies to disclose.

Matthew C. Altman, MD – Speaker
Payel Gupta, MD – Speaker
Kristina James, MD – Speaker
Albert Tsien, MD – Planner, Moderator
Karol Anderson - Planner

Available Credit

  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Please login or create an account to take this course.